Market Overview

Magellan Health Reports Second Quarter 2018 Financial Results

Share:

Lowers 2018 Guidance

Magellan
Health, Inc.
(NASDAQ:MGLN) today announced financial results for
the second quarter ended June 30, 2018, as summarized below:

       

Three Months Ended
June 30

Six Months Ended
June 30
(In millions, except per share amounts)        

2018

2017

Chg

2018

2017

Chg

Net revenue $ 1,810.9 $ 1,419.1 27.6 % $ 3,616.0 $ 2,724.8 32.7 %
Net income $ 13.6 $ 5.5 146.4 % $ 25.0 $ 23.2 7.6 %
Segment profit [1] $ 68.0 $ 54.3 25.2 % $ 123.6 $ 124.2 -0.5 %
Adjusted net income [1] $ 23.3 $ 14.1 65.2 % $ 44.1 $ 40.2 9.7 %
Per share results:
Earnings per share $ 0.53 $ 0.23 130.4 % $ 0.98 $ 0.97 1.0 %
Adjusted earnings per share [1] $ 0.92 $ 0.59 55.9 % $ 1.73 $ 1.67 3.6 %
 
[1] Refer to the Basis of Presentation for a discussion
of non-GAAP financial measures.
 

Highlights Include:

  • Net revenue increased 27.6 percent over the second quarter of 2017 to
    $1.8 billion.
  • Net income increased 146.4 percent over the second quarter of 2017 to
    $13.6 million.
  • Segment profit increased 25.2 percent over the second quarter of 2017
    to $68.0 million.
  • Adjusted net income increased 65.2 percent from the second quarter of
    2017 to $23.3 million.
  • Unrestricted cash and investments were $244.4 million as of June 30,
    2018. Approximately $115.8 million of the unrestricted cash and
    investments as of June 30, 2018, is related to excess capital and
    undistributed earnings held at regulated entities.
  • On May 24, 2018, the Company's board of directors approved an
    additional $200 million to the current $200 million stock repurchase
    plan which will now authorize the Company to purchase up to $400
    million. The board also extended the end date for an additional two
    years until October 22, 2020.
  • In May, the Company was named to the annual Fortune 500 list of
    America's largest corporations by revenue for the first time in the
    Company's history.

Net Revenue

Net revenue for the second quarter ended June 30, 2018, was $1.8
billion, an increase of 27.6 percent over the same period in 2017. This
increase was mainly driven by net business growth and the annualization
of revenue from the prior year acquisition of Senior Whole Health.

Segment Profit

Segment profit was $68.0 million for the second quarter, compared to
$54.3 million in the prior year quarter.

  • Healthcare segment profit was $43.9 million, which represents an
    increase of 46.2 percent over the second quarter of 2017. The increase
    was mainly due to several factors, including: the incremental
    contribution of the Senior Whole Health acquisition; $8 million of
    favorable out of period development in the current quarter, the
    majority of which relates to the first quarter 2018; and net
    improvements in our Commercial business; partially off-set by a rate
    reduction in Florida and operating losses in Virginia.
  • Pharmacy management segment profit was $29.9 million, which was a
    decrease of 11.7 percent from the second quarter of 2017. This
    decrease was primarily driven by a decline in earnings in our
    specialty carve-out business resulting from lost formulary management
    contracts.
  • Corporate costs inclusive of eliminations, but excluding stock
    compensation expense, totaled $5.8 million, compared to $9.6 million
    in the second quarter of 2017. This decrease was largely due to lower
    discretionary benefit expenses.

Cash Flow & Balance Sheet

Cash flow from operations for the six months ended June 30, 2018, was
$21.1 million versus $3.8 million in the six months ended June 30, 2017.
The improved cash flow in the current year is mainly attributable to a
decrease in tax payments and other net favorable working capital changes.

As of June 30, 2018, the Company's unrestricted cash and investments
totaled $244.4 million, which represents a decrease of $16.8 million
from the balance at December 31, 2017. Approximately $115.8 million of
the unrestricted cash and investments at June 30, 2018, is related to
excess capital and undistributed earnings held at regulated entities.

Restricted cash and investments at June 30, 2018, was $435.0 million
versus the balance at December 31, 2017 of $465.4 million.

On May 24, 2018, the Company's board of directors approved an additional
$200 million to the current $200 million stock repurchase plan which now
authorizes the Company to purchase up to $400 million. The board also
extended the end date for an additional two years until October 22,
2020. As of July 20, 2018, the total remaining under this increased
authorization was $234.6 million.

Outlook

The Company is lowering its 2018 full year earnings guidance.

"We are updating our guidance ranges to reflect the following: the
impact of lost contracts and delays in closing on pipeline opportunities
in our pharmacy specialty carve-out business; the impact of our
continued cost of care pressure in Virginia; and in New York, the impact
of lower than expected membership growth as well as lower than
anticipated capitation rates, partially offset by improvements in care
management," said Jonathan N. Rubin, chief financial officer of Magellan
Health.

The Company now anticipates segment profit in the range of $330 million
to $350 million. In addition, the Company expects revenue in the range
of $7.3 billion to $7.5 billion, net income in the range of $93 million
to $117 million, adjusted net income in the range of $132 million to
$152 million, EPS in the range of $3.65 to $4.59 and adjusted EPS in the
range of $5.18 to $5.96.

"Compared to the first half of 2018, we expect the segment profit to
sequentially increase for the remainder of the year due to the following
three factors: earnings seasonality in both our healthcare and pharmacy
businesses, margin expansion due to initiatives in our healthcare
segment, and new business and same store growth," said Rubin. "While we
expect these items to have a favorable impact in the third quarter, we
anticipate a greater impact in the fourth quarter."

"I am confident in our strategy and optimistic about our continued
growth trajectory," said Barry M. Smith, chairman and chief executive
officer of Magellan Health. "2018 will continue to be a year of focused
execution for Magellan, and our strategy remains unchanged."

       
2018 Guidance July 27, 2018 April 26, 2018

Low

 

High

Low

 

High

Net revenue $ 7,300.0 $ 7,500.0 $ 7,500.0 $ 7,800.0
Income before income taxes $ 132.0 $ 170.0 $ 165.0 $ 203.0
Net income $ 93.0 $ 117.0 $ 113.0 $ 137.0
Segment Profit[1] $ 330.0 $ 350.0 $ 365.0 $ 385.0
Adjusted net income[1] $ 132.0 $ 152.0 $ 151.0 $ 171.0
 
Per share results:
Earnings per share[2] $ 3.65 $ 4.59 $ 4.41 $ 5.35
Adjusted earnings per share[1][2] $ 5.18 $ 5.96 $ 5.90 $ 6.68
 
[1] Refer to the Basis of Presentation for a discussion
of non-GAAP financial measures.

[2] 2018 EPS and Adjusted EPS guidance includes share
repurchases and option exercises through the close of business
July 20, 2018, but excludes the impact of any potential future
activity.

 

Earnings Conference Call

Management will discuss the Company's second quarter results on a
conference call scheduled for Friday, July 27, 2018 at 8:00 a.m.
Eastern. To participate in the conference call, dial 1-800-857-1812 and
use passcode "2nd Quarter 2018" approximately 10 minutes
before the start of the call. The conference call will also be available
live via webcast at Magellan's investor relations page at MagellanHealth.com.
A telephonic replay will be available shortly after the conclusion of
the call through August 26, 2018. This replay may be accessed by dialing
1-866-501-5116 (Domestic) or 1-203-369-1840 (International). A replay of
the webcast will also be available at the site listed above for 30 days,
beginning approximately two hours after its conclusion.

Basis of Presentation

In addition to results determined under Generally Accepted Accounting
Principles (GAAP), Magellan provides certain non-GAAP financial measures
that management believes are useful in assessing the Company's
performance. Following is a description of these important non-GAAP
measures.

Segment profit is equal to net revenue less the sum of cost of care,
cost of goods sold, direct service costs and other operating expenses,
and includes income from unconsolidated subsidiaries, but excludes
segment profit or loss from non-controlling interests held by other
parties, stock compensation expense, special charges or benefits, as
well as changes in the fair value of contingent consideration recorded
in relation to acquisitions.

Adjusted net income and adjusted earnings per share reflect certain
adjustments made for acquisitions completed after January 1, 2013, to
exclude non-cash stock compensation expense resulting from restricted
stock purchases by sellers, changes in the fair value of contingent
consideration, amortization of identified acquisition intangibles, as
well as impairment of identified acquisition intangibles.

Included in the tables issued with this press release are the
reconciliations from GAAP measures to the corresponding non-GAAP
measures.

About Magellan Health: Magellan
Health, Inc.
, a Fortune
500 company
, is a leader in managing the fastest growing, most
complex areas of health, including special populations, complete
pharmacy benefits and other specialty areas of healthcare. Magellan
supports innovative ways of accessing better health through technology,
while remaining focused on the critical personal relationships that are
necessary to achieve a healthy, vibrant life. Magellan's customers
include health plans and other managed care organizations, employers,
labor unions, various military and governmental agencies and third-party
administrators. For more information, visit MagellanHealth.com.

Forward-Looking Statements

This release is intended to be disclosure through methods reasonably
designed to provide broad, non-exclusionary distribution to the public
in compliance with the Securities and Exchange Commission's Fair
Disclosure Regulation. This release contains forward-looking statements
within the meaning of the Securities Exchange Act of 1934 and the
Securities Act of 1933, as amended, which involve a number of risks and
uncertainties, many of which are out of our control. All statements,
other than statements of historical information provided herein, may be
deemed to be forward-looking statements including, without limitation,
statements regarding 2018 guidance for net revenue, income before income
taxes, net income, earnings per share, segment profit, adjusted net
income, adjusted earnings per share, growth opportunities and strategy.
These statements are based on management's analysis, judgment, belief
and expectation only as of the date hereof, and are subject to
uncertainty and changes in circumstances. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"may," "should," "could," "estimate," "intend" and other similar
expressions are intended to identify forward-looking statements. Actual
results could differ materially due to, among other things, the possible
election of certain of the Company's customers to manage the healthcare
services of their members directly; changes in rates paid to and/or by
the Company by customers and/or providers; higher utilization of
healthcare services by the Company's risk members; delays, higher costs
or inability to implement new business or other Company initiatives; the
impact of changes in the contracting model for Medicaid contracts;
termination or non-renewal of customer contracts; the impact of new or
amended laws or regulations; governmental inquiries; litigation;
competition; operational issues; healthcare reform; and general business
conditions. Additional factors that could cause actual results to differ
materially from those reflected in the forward-looking statements
include, but are not limited to, the risks discussed in the "Risk
Factors" section included within the Company's Annual Report on Form
10-K for the year ended December 31, 2017, filed with the Securities and
Exchange Commission on March 1, 2018, and the Company's subsequent
Quarterly Reports on Form 10-Q filed during 2018. Readers are cautioned
not to place undue reliance on these forward-looking statements. The
Company undertakes no obligation to publicly revise these
forward-looking statements to reflect events or circumstances that arise
after the date of this release. Segment profit, adjusted net income, and
adjusted EPS information referred to herein may be considered a non-GAAP
financial measure. Further information regarding these measures,
including the reasons management considers this information useful to
investors, are included in the Company's most recent Annual Report on
Form 10-K and on subsequent Form 10-Qs.

       
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands)
 
       
December 31, 2017 June 30, 2018
(unaudited)
ASSETS
 
Current Assets:
Cash and cash equivalents $ 398,732 $ 246,109
Accounts receivable, net 660,775 839,773
Short-term investments 310,578 412,770
Pharmaceutical inventory 40,945 50,333
Other current assets   72,323     119,164  
Total Current Assets 1,483,353 1,668,149
Property and equipment, net 158,638 160,702
Long-term investments 17,287 20,478
Deferred income taxes 813 1,554
Other long-term assets 22,567 30,909
Goodwill 1,006,288 1,014,321
Other intangible assets, net   268,288     243,646  
Total Assets $ 2,957,234   $ 3,139,759  
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
Current Liabilities:
Accounts payable $ 74,300 $ 76,458
Accrued liabilities 193,635 268,258
Short-term contingent consideration 6,892 7,062
Medical claims payable 327,625 397,550
Other medical liabilities 177,002 183,222
Current debt and capital lease obligations   112,849     90,546  
Total Current Liabilities 892,303 1,023,096
Long-term debt and capital lease obligations 740,888 734,503
Deferred income taxes 12,298 10,928
Tax contingencies 14,226 15,058
Long-term contingent consideration 1,925 2,058
Deferred credits and other long-term liabilities   19,100     35,346  
Total Liabilities   1,680,740     1,820,989  
 
Stockholders' Equity:
Ordinary common stock 530 535
Additional paid-in capital 1,274,811 1,311,316
Retained earnings 1,399,495 1,420,271
Accumulated other comprehensive loss (380 ) (567 )
Ordinary common stock in treasury, at cost   (1,397,962 )   (1,412,785 )
Total Stockholders' Equity   1,276,494     1,318,770  
Total Liabilities and Stockholders' Equity $ 2,957,234   $ 3,139,759  
 
 
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
(In thousands, except per share amounts)
               
 

Three Months Ended
June 30,

Six Months Ended
June 30,
2017 2018 2017 2018
 
Net revenue:
Managed care and other $ 821,699 $ 1,215,340 $ 1,551,039 $ 2,435,103
PBM   597,440     595,583     1,173,723     1,180,897  
Total net revenue   1,419,139     1,810,923     2,724,762     3,616,000  
 
Costs and expenses:
Cost of care 583,264 935,814 1,065,318 1,864,475
Cost of goods sold 562,355 558,419 1,104,988 1,118,084
Direct service costs and other operating expenses (1)(2) 231,372 259,152 452,858 528,229
Depreciation and amortization 27,731 33,848 54,707 64,255
Interest expense 4,900 8,678 9,048 17,044
Interest and other income   (1,071 )   (3,363 )   (2,020 )   (5,839 )
Total costs and expenses   1,408,551     1,792,548     2,684,899     3,586,248  
Income before income taxes 10,588 18,375 39,863 29,752
Provision for income taxes   5,661     4,824     17,467     4,749  
Net income 4,927 13,551 22,396 25,003
Less: net loss attributable to non-controlling interest   (573 )   -     (851 )   -  
Net income attributable to Magellan $ 5,500   $ 13,551   $ 23,247   $ 25,003  
 
Weighted average number of common shares outstanding — basic 23,108 24,569 23,060 24,460
Weighted average number of common shares outstanding — diluted 24,038 25,407 24,037 25,510
 
Net income attributable to Magellan per common share — basic $ 0.24 $ 0.55 $ 1.01 $ 1.02
Net income attributable to Magellan per common share — diluted $ 0.23 $ 0.53 $ 0.97 $ 0.98
 
Net income $ 4,927 $ 13,551 $ 22,396 $ 25,003
Other comprehensive income:
Unrealized gain (loss) on available-for-sale securities (3)   22     132     1     (187 )
Comprehensive income 4,949 13,683 22,397 24,816
Less: comprehensive loss attributable to non-controlling interest   (573 )   -     (851 )   -  
Comprehensive income attributable to Magellan $ 5,522   $ 13,683   $ 23,248   $ 24,816  
 
(1) Includes stock compensation expense of $11,371 and $10,439 for
the three months ended June 30, 2017 and 2018, respectively, and
$21,511 and $18,085 for the six months ended June 30, 2017 and 2018,
respectively.
 
(2) Includes changes in fair value of contingent consideration of
$252 and $70 for the three months ended June 30, 2017 and 2018,
respectively, and $203 and $303 for the six months ended June 30,
2017 and 2018, respectively.
 
(3) Net of income tax provision (benefit) of $14 and $42 for the
three months ended June 30, 2017 and 2018, respectively, and $2 and
$(59) for the six months ended June 30, 2017 and 2018, respectively.
 
 
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
       
 
Six Months Ended
June 30,
2017 2018
Cash flows from operating activities:
Net income $ 22,396 $ 25,003
Adjustments to reconcile net income to net cash from operating
activities:
Depreciation and amortization 54,707 64,255
Non-cash interest expense 578 614
Non-cash stock compensation expense 21,511 18,085
Non-cash income tax benefit (1,520 ) (100 )
Non-cash amortization on investments 2,094 1,171
Changes in assets and liabilities, net of effects from acquisitions
of businesses:
Accounts receivable, net (21,859 ) (179,350 )
Pharmaceutical inventory (1,188 ) (9,388 )
Other assets (21,974 ) (57,398 )
Accounts payable and accrued liabilities (59,372 ) 50,322
Medical claims payable and other medical liabilities 5,978 89,932
Contingent consideration 203 303
Tax contingencies 764 721
Deferred credits and other long-term liabilities 1,882 16,884
Other   (364 )   69  
Net cash provided by operating activities   3,836     21,123  
 
Cash flows from investing activities:
Capital expenditures (26,797 ) (37,132 )
Acquisitions and investments in businesses, net of cash acquired (3,200 ) -
Purchase of investments (238,814 ) (334,250 )
Maturity of investments   233,143     227,446  
Net cash used in investing activities   (35,668 )   (143,936 )
 
Cash flows from financing activities:
Proceeds from issuance of debt 200,000 -
Payments to acquire treasury stock (5,000 ) (14,323 )
Proceeds from exercise of stock options 5,946 21,476
Payments on debt and capital lease obligations (190,978 ) (33,912 )
Other   (1,311 )   (3,051 )
Net cash provided by (used in) financing activities   8,657     (29,810 )
 
Net decrease in cash and cash equivalents (23,175 ) (152,623 )
Cash and cash equivalents at beginning of period   304,508     398,732  
Cash and cash equivalents at end of period $ 281,333   $ 246,109  
 
               
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT
(Unaudited)
(In thousands)
 
 
Three Months Ended Six Months Ended
June 30, June 30,
2017 2018 2017 2018

Healthcare

Managed care and other revenue $ 755,270 $ 1,154,888 $ 1,420,646 $ 2,312,489
Cost of care (583,264 ) (935,814 ) (1,065,318 ) (1,864,475 )
Direct service costs and other (145,914 ) (177,990 ) (284,882 ) (364,236 )
Stock compensation expense (1) 3,106 2,742 5,765 5,692
Changes in fair value of contingent consideration (1) 252 70 203 303
Less: non-controlling interest segment loss (2)   (568 )   -     (845 )   -  
Healthcare segment profit 30,018 43,896 77,259 89,773
 

Pharmacy Management

Managed care and other revenue 66,659 60,603 130,839 122,910
PBM revenue 631,932 642,794 1,238,678 1,274,992
Cost of goods sold (595,446 ) (603,951 ) (1,167,283 ) (1,208,864 )
Direct service costs and other (74,953 ) (70,941 ) (150,806 ) (146,527 )
Stock compensation expense (1)   5,684     1,408     11,414     2,893  
Pharmacy Management segment profit 33,876 29,913 62,842 45,404
 

Corporate and Elimination (3)

Managed care and other revenue (230 ) (151 ) (446 ) (296 )
PBM revenue (34,492 ) (47,211 ) (64,955 ) (94,095 )
Cost of goods sold 33,091 45,532 62,295 90,780
Direct service costs and other (10,505 ) (10,221 ) (17,170 ) (17,466 )
Stock compensation expense (1) 2,581 6,289 4,332 9,500
Less: non-controlling interest segment loss (2)   (1 )   -     (2 )   -  
Corporate and Elimination (9,554 ) (5,762 ) (15,942 ) (11,577 )
 

Consolidated

Managed care and other revenue 821,699 1,215,340 1,551,039 2,435,103
PBM revenue 597,440 595,583 1,173,723 1,180,897
Cost of care (583,264 ) (935,814 ) (1,065,318 ) (1,864,475 )
Cost of goods sold (562,355 ) (558,419 ) (1,104,988 ) (1,118,084 )
Direct service costs and other (231,372 ) (259,152 ) (452,858 ) (528,229 )
Stock compensation expense (1) 11,371 10,439 21,511 18,085
Changes in fair value of contingent consideration (1) 252 70 203 303
Less: non-controlling interest segment loss (2)   (569 )   -     (847 )   -  
Consolidated segment profit $ 54,340   $ 68,047   $ 124,159   $ 123,600  
 
 
Reconciliation of income before income taxes to segment profit:
Income before income taxes $ 10,588 $ 18,375 $ 39,863 $ 29,752
Stock compensation expense 11,371 10,439 21,511 18,085
Changes in fair value of contingent consideration 252 70 203 303
Non-controlling interest segment loss 569 - 847 -
Depreciation and amortization 27,731 33,848 54,707 64,255
Interest expense 4,900 8,678 9,048 17,044
Interest and other income   (1,071 )   (3,363 )   (2,020 )   (5,839 )
Segment profit $ 54,340   $ 68,047   $ 124,159   $ 123,600  
 
 
(1) Stock compensation expense, changes in the fair value of
contingent consideration recorded in relation to acquisitions and
impairment of intangible assets are included in direct service costs
and other operating expenses; however, these amounts are excluded
from the computation of segment profit.
 
(2) The non-controlling portion of AlphaCare's segment loss is
excluded from the computation of segment profit.
 
(3) Healthcare subcontracts with Pharmacy Management to provide
pharmacy benefits management services for certain of Healthcare's
customers. In addition, Pharmacy Management provides pharmacy
benefits management for the Company's employees covered under its
medical plan. As such, revenue, cost of goods sold and direct
service costs and other related to these arrangements are eliminated.
 
               
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NON-GAAP MEASURES
(Unaudited)
(In thousands, except per share amounts)
 
 
Three Months Ended Six Months Ended
June 30, June 30,
2017 2018 2017 2018
 
Net income attributable to Magellan $ 5,500 $ 13,551 $ 23,247 $ 25,003
Adjusted for acquisitions starting in 2013
Stock compensation expense relating to acquisitions 4,906 268 9,758 530
Changes in fair value of contingent consideration 252 70 203 303
Amortization of acquired intangibles 8,315 12,726 16,766 24,597
Tax impact   (4,888 )   (3,344 )   (9,767 )   (6,357 )
Adjusted net income $ 14,085   $ 23,271   $ 40,207   $ 44,076  
 
 
Net income per common share attributable to Magellan —diluted $ 0.23 $ 0.53 $ 0.97 $ 0.98
Adjusted for acquisitions starting in 2013
Stock compensation expense relating to acquisitions 0.20 0.01 0.40 0.02
Changes in fair value of contingent consideration 0.01 - 0.01 0.01
Amortization of acquired intangibles 0.35 0.51 0.70 0.97
Tax impact   (0.20 )   (0.13 )   (0.41 )   (0.25 )
Adjusted earnings per share $ 0.59   $ 0.92   $ 1.67   $ 1.73  
 
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
FISCAL 2018 GUIDANCE
(In millions, except per share amounts)
 
 
      April 26, 2018     July 27, 2018
Low     High Low     High
 
Net revenue $ 7,500.0     $ 7,800.0 $ 7,300.0     $ 7,500.0
Income before income taxes 165.0 203.0 132.0 170.0
Net income 113.0 137.0 93.0 117.0
Segment profit (1) 365.0 385.0 330.0 350.0
Adjusted net income (1) 151.0 171.0 132.0 152.0
Per share results:
Earnings per share (2) 4.41 5.35 3.65 4.59
Adjusted earnings per share (1)(2) 5.90 6.68 5.18 5.96
 
 
(1) Refer to the Reconciliation of GAAP to Non-GAAP measures table.
 
(2) Based on average fully diluted shares of 25.6 million and 25.5
million for previous guidance and current guidance, respectively.
 
 
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
FISCAL 2018 GUIDANCE
RECONCILIATION OF GAAP TO NON-GAAP MEASURES
(In millions, except per share amounts)
 
 
      April 26, 2018     July 27, 2018
Low     High Low     High
 
Net income attributable to Magellan $ 113.0     $ 137.0 $ 93.0     $ 117.0
Adjusted for acquisitions starting in 2013
Stock compensation expense relating to acquisitions 1.0 1.0 1.0 1.0
Changes in fair value of contingent consideration - - - -
Amortization of acquired intangibles 51.0 45.0 52.0 47.0
Tax impact   (14.0 )   (12.0 )   (14.0 )   (13.0 )
Adjusted net income $ 151.0   $ 171.0   $ 132.0   $ 152.0  
 
 
 
Net income per common share attributable to Magellan —Diluted $ 4.41 $ 5.35 $ 3.65 $ 4.59
Adjusted for acquisitions starting in 2013
Stock compensation expense relating to acquisitions 0.04 0.04 0.04 0.04
Changes in fair value of contingent consideration - - - -
Amortization of acquired intangibles 1.99 1.76 2.04 1.84
Tax impact   (0.54 )   (0.47 )   (0.55 )   (0.51 )
Adjusted earnings per share $ 5.90   $ 6.68   $ 5.18   $ 5.96  
 
 
 
Reconciliation of income before income taxes to segment profit:
Income before income taxes $ 165.0 $ 203.0 $ 132.0 $ 170.0
Stock compensation expense 37.0 33.0 35.0 33.0
Changes in fair value of contingent consideration - - - -
Depreciation and amortization 136.0 126.0 137.0 127.0
Interest expense 37.0 33.0 37.0 33.0
Interest income   (10.0 )   (10.0 )   (11.0 )   (13.0 )
Segment profit $ 365.0   $ 385.0   $ 330.0   $ 350.0  
 

(MGLN-GEN)

View Comments and Join the Discussion!